uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.
Uniqure Nv stock last closed at $22.74, down 10.75% from the previous day, and has increased 261.53% in one year. It has overperformed other stocks in the Biotechnology industry by 3.09 percentage points. Uniqure Nv stock is currently +243.5% from its 52-week low of $6.62, and -68.2% from its 52-week high of $71.50.
As of Dec 4, 2025, there are 62.29M shares of QURE outstanding. The market cap of QURE is $1.42B. In the past 24 hours, 9.1M QURE shares were traded.
You will need an online brokerage account in order to access the NASDAQ market and buy QURE shares.
Based on our research, eToro is the best online stock brokerage. eToro gives you:
Get $10 towards your purchase of shares by creating an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, you need to fill out some personal information so you are able to invest in QURE stock today.
Now that you have filled out your info on the best stock market app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring money into your new investment account.
After you have decided on the best place to buy Uniqure Nv stock, it's critical to analyze their stock before you invest, so you can wrap your head around the risk as well as the upside.
WallStreetZen was created to help average investors perform more accurate fundamental analysis in less time.
You can see all of the due diligence checks on QURE's stock page.
You can use many financial metrics, analyses, models, and charts to gauge QURE's fair value.
Using relative valuations metrics:
You can access more valuation research on QURE's stock here.
Out of 10 Wall Street analysts who research QURE, the consensus analyst rating on Uniqure Nv is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Patrick R. Trucchio, a top 10% analyst from HC Wainwright & Co. maintains QURE with a buy rating and lowers their QURE price target from $110.00 to $70.00, on Nov 4, 2025.
Uy Ear, a top 22% analyst from Mizuho maintains QURE with a buy rating and raises their QURE price target from $30.00 to $60.00, on Sep 25, 2025.
Debjit Chattopadhyay, a top 9% analyst from Guggenheim maintains QURE with a strong buy rating and raises their QURE price target from $28.00 to $95.00, on Sep 25, 2025.
Kristen Kluska, a top 2% analyst from Cantor Fitzgerald maintains QURE with a strong buy rating and raises their QURE price target from $47.00 to $80.00, on Sep 25, 2025.
Cantor Fitzgerald's Kristen Kluska raised their price target on Uniqure Nv (NASDAQ: QURE) by 70.2% from $47 to $80 on 2025/09/25. The analyst maintained their Strong Buy rating on the stock.
On 2025/09/24, uniQure NV announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease.
Although some patients may want to wait for AMT-130 approval before taking action, the patient advocacy community is very enthusiastic about the drug, Kluska told readers.
The analyst said they are bullish that the past three years could back approval and adoption.
Kluska said the success likelihood of AMT-130 in the U.S. and in Europe has increased from 45% to 75% and from 15% to 45%, respectively.
Paul Matteis, a top 40% analyst from Stifel Nicolaus maintains QURE with a strong buy rating and raises their QURE price target from $30.00 to $65.00, on Sep 24, 2025.
You can dive deeper into what analysts are forecasting on the Uniqure Nv stock forecast page.
Last year, QURE revenue was $15.75M. Over the last five year, QURE's revenue has gone up by 21.08% per year. This was slower than the Biotechnology industry average of 43.9%.
Dive into QURE's earnings and revenue performance here.
Over the last 12 months, executives and large shareholders at QURE have sold more shares than they have bought.
Robert Gut, Director of QURE, was the latest QURE insider to buy. They bought $72,388.80 worth of QURE stock on Nov 6, 2025.
Get more info about who owns QURE shares here.
No, Uniqure Nv doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
You have two main types of orders:
Hit the Open button and eToro will execute your order.
If you require additional assistance investing in stocks on eToro, watch the helpful video below:
Now that you own some QURE stock, you'll want to stay up-to-date on your new shares.
Start a watchlist to get alerted to the latest events about your QURE stock.
To summarize, here are the 6 steps to buy stock in Uniqure Nv:
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Uniqure Nv, create a watchlist on WallStreetZen today.